Últimas noticias sobre Amprius Technologies (NYSE:AMPX) Bolsa

Amprius Technologies

Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites.

Amprius Technologies Inc

Amprius Technologies, Inc. Warrants to purchase one share of Common Stock at an exercise price of $11.50 per share

<a target="_blank" href="https://www.benzinga.com/quote/VERV" rel="noreferrer noopener">Verve Therapeutics Inc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), which requires reducing low-density lipoprotein cholesterol (LDL-C) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">levels in the blood</a>.
VERVE-102 was well-tolerated among 14 participants across three dose levels. No treatment-related serious adverse events (SAEs) and no clinically significant laboratory <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44785340/verve-therapeutics-announces-positive-initial-data-from-the-heart-2-phase-1b-clinical-trial-of-ver" rel="noreferrer noopener">abnormalities were observed</a>.
A single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 protein (regulates cholesterol metabolism) levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.
VERVE-102 is a novel,&nbsp;in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the&nbsp;PCSK9&nbsp;gene in the liver and durably reduces disease-driving LDL-C.
<ul>
<li>VERVE-102 comprises an adenine base editor and a guide RNA (gRNA) targeting the&nbsp;PCSK9&nbsp;gene. Both are encapsulated in a lipid nanoparticle (LNP) and administered as a single intravenous infusion over two to four hours.</li>
</ul>
VERVE-102 has been well-tolerated, with no treatment-related SAEs, dose-limiting toxicities, or cardiovascular events observed.
Following a single infusion of VERVE-102, dose-dependent reductions in two pharmacodynamic (PD) measures were observed: blood LDL-C and PCSK9 protein levels.
<ul>
<li>Cohort 1; 0.3 mg/kg (n=4): LDL-C reduction was 21% and PCSK9 reduction was 46%.</li>
<li>Cohort 2; 0.45 mg/kg (n=6): LDL-C reduction was 41% and PCSK9 reduction was 53%.</li>
<li>Cohort 3; 0.6 mg/kg (n=4): LDL-C reduction was 53% and PCSK9 reduction was 60%.</li>
</ul>
Across all 14 participants, VERVE-102 demonstrated a strong dose-dependent response between the amount of total RNA administered and LDL-C reductions.
The Heart-2 trial is enrolling participants in the fourth dose cohort of 0.7 mg/kg. Verve has dosed two participants in this cohort.
<ul>
<li>Verve expects to announce the final data from the dose escalation portion of the Heart-2 clinical trial, including durability data, in the second half of 2025.</li>
<li>Verve plans to dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025, subject to regulatory clearance.</li>
</ul>
Verve expects its current capital position to be sufficient to fund its operations into mid-2027, which includes the completion of the Phase 2 clinical trial.
Under the PCSK9 program collaboration agreement with Verve, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) holds the right to opt-in to share worldwide development expenses (33% contributed by Lilly) and to jointly commercialize and share profits and expenses related to commercialization in the U.S. on a 50/50 basis.
<ul>
<li>Verve retains control of the development and commercialization of all collaboration products in the U.S., and Verve holds all product rights outside the U.S.</li>
<li>Verve expects to deliver the opt-in package for the PCSK9 program and receive a decision from Lilly in the second half of 2025.</li>
</ul>
Last week, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VERVE-102 for hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44757920/verve-therapeutics-receives-u-s-fda-fast-track-designation-for-verve-102-an-in-vivo-base-editing-m" rel="noreferrer noopener">cholesterol (LDL-C)</a>.
Price Action: VERV stock is up 13% at $3.69 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/04/44785962/accenture-partners-with-goupscale-to-scale-relationship-management-in-asias-digital-wealth-boom" target="_blank" rel="noreferrer noopener">Accenture Partners With GoUpscale To Scale Relationship Management In Asia&#8217;s Digital Wealth Boom</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

News

Health Care

Movers

Trading Ideas

General

VERV

Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose

Raymond James analyst Simon Leopold maintains Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) with a Outperform and lowers the price target from $31 to $20.

Price Target

Analyst Ratings

AAOI

Raymond James Maintains Outperform on Applied Optoelectronics, Lowers Price Target to $20

Scotiabank analyst Ovais Habib maintains Rupert Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RUP#TSX">RUP</a>) with a Sector Outperform and lowers the price target from C$10 to C$7.

TSX:RUP

Scotiabank Maintains Sector Outperform on Rupert Resources, Lowers Price Target to C$7

Susquehanna analyst Charles Minervino maintains MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) with a Positive and lowers the price target from $15 to $13.

Susquehanna Maintains Positive on MRC Global, Lowers Price Target to $13

Scotiabank analyst Ovais Habib maintains Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) with a Sector Outperform and raises the price target from $28.5 to $32.

PAAS

Scotiabank Maintains Sector Outperform on Pan American Silver, Raises Price Target to $32

Susquehanna analyst Charles Minervino maintains Dnow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNOW#NYSE">DNOW</a>) with a Neutral and lowers the price target from $19 to $18.

DNOW

Susquehanna Maintains Neutral on Dnow, Lowers Price Target to $18

Susquehanna analyst Biju Perincheril maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Neutral and lowers the price target from $17 to $12.

SEDG

Susquehanna Maintains Neutral on SolarEdge Technologies, Lowers Price Target to $12

Susquehanna analyst Biju Perincheril maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Positive and lowers the price target from $13 to $10.

Susquehanna Maintains Positive on Sunrun, Lowers Price Target to $10

Scotiabank analyst Ovais Habib maintains Orla Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/OLA#TSX">OLA</a>) with a Sector Outperform and raises the price target from C$8.75 to C$15.5.

TSX:OLA

Scotiabank Maintains Sector Outperform on Orla Mining, Raises Price Target to C$15.5

Susquehanna analyst Biju Perincheril maintains Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) with a Neutral and lowers the price target from $1.8 to $1.25.

PLUG

Susquehanna Maintains Neutral on Plug Power, Lowers Price Target to $1.25

Scotiabank analyst Eric Winmill maintains New Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NGD#AMEX">NGD</a>) with a Sector Outperform and raises the price target from $4.25 to $4.75.

Scotiabank Maintains Sector Outperform on New Gold, Raises Price Target to $4.75

Scotiabank analyst Ovais Habib maintains MAG Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#AMEX">MAG</a>) with a Sector Outperform and raises the price target from $18 to $18.5.

Scotiabank Maintains Sector Outperform on MAG Silver, Raises Price Target to $18.5

Crude oil prices have come under pressure from ongoing trade tensions between the U.S. and China, which have cast uncertainty over global growth and fuel demand. Last week, Energy Secretary Chris Wright spoke positively about the oil and shale industry despite the <a href="https://www.benzinga.com/25/04/44667862/oil-crashes-to-60-per-barrel-as-recession-fears-grow">steep drop in prices.</a> 
What to Know: Wright, a former CEO of Liberty Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) with firsthand experience in the shale sector, <a href="https://www.cnbc.com/2025/04/11/us-energy-secretary-bullish-on-shale-despite-plunging-oil-prices-.html">told</a> CNBC in an interview that he remains optimistic about the industry&#8217;s ability to adapt and prosper. 
"The U.S. shale industry is going to survive and thrive," Wright said.
"But of course, investment decisions are going to be tailored if prices stay this low for a long period of time. But I'm quite bullish on the U.S. industry," he added.&nbsp;
Read Next:<a href="https://www.benzinga.com/news/global/25/04/44762211/10-companies-with-exposure-to-trumps-china-tariff-war-ford-tesla-apple-disney-and-more"> 10 Companies With Exposure To Trump&#8217;s China Tariff War: Ford, Tesla, Apple, Disney And More&nbsp;</a>
Crude oil prices are down nearly 27% in 2025, trading below the key $65 per barrel threshold identified by the Federal Reserve Bank of Dallas as the break-even point for Permian Basin operators like Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>). 
Still, Wright highlighted the oil industry's ability to innovate and referenced the 2014–2016 downturn when shale production surged amid weak demand.&nbsp;
"In 2015 and 2016 oil prices twice hit $28, and what happened? What did the U.S. shale industry do in that time — innovate, get smarter, drive their costs down, and that's what's happening right now," Wright said.
What Else: Energy analysts at Goldman Sachs recently reduced their oil forecasts for December 2025 to $62 per barrel for Brent and $58 for WTI, with additional downside expected in 2026. The analysts noted GDP downgrades and forecasts of a "stagnating" U.S. economy.&nbsp;
Adding to the pressure on oil prices, OPEC+ oil producers recently announced a massive production increase to 411,000 barrels per day next month. Meanwhile, the group <a href="https://www.opec.org/monthly-oil-market-report.html">cut its</a> 2025–26 global oil demand growth forecast on Monday by 100,000 barrels per day due to slower growth resulting from Trump's tariffs. 
OPEC said it expects 1.3 million barrels per day growth each year, still above estimates from others like the EIA of 900,000 and Goldman Sachs estimate of 500,000.&nbsp;
The United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), which tracks the daily price movements of light, sweet crude oil, was up 0.43% at the time of publication on Monday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44695907/elon-musk-calls-trump-trade-advisor-peter-navarro-dumber-than-sack-of-bricks-defends-tesla-as-the-most-american-made-cars">Elon Musk Calls Trump Trade Advisor Peter Navarro &#8216;Dumber Than Sack Of Bricks,&#8217; Defends Tesla As &#8216;Most American-Made Cars&#8217;&nbsp;</a></li>
</ul>
Image: Shutterstock

Commodities

Politics

Global

Markets

LBRT

Energy Secretary Chris Wright Is 'Bullish' As Oil Prices Crater

Susquehanna analyst Biju Perincheril maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Positive and lowers the price target from $223 to $217.

FSLR

Susquehanna Maintains Positive on First Solar, Lowers Price Target to $217

Scotiabank analyst Ovais Habib maintains Lundin Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LUG#TSX">LUG</a>) with a Sector Perform and raises the price target from C$32.5 to C$43.

TSX:LUG

Scotiabank Maintains Sector Perform on Lundin Gold, Raises Price Target to C$43

WIIM

CHRS

Coherus BioSciences shares are trading higher after the company announced it completed UDENYCA franchise divestiture.

<a href="https://www.bloomberg.com/news/articles/2025-04-14/meta-faces-potential-breakup-with-ftc-antitrust-trial-starting" title="https://www.bloomberg.com/news/articles/2025-04-14/meta-faces-potential-breakup-with-ftc-antitrust-trial-starting">https://www.bloomberg.com/news/articles/2025-04-14/meta-faces-potential-breakup-with-ftc-antitrust-trial-starting</a>

Legal

'Meta Faces Potential Breakup With Start Of Antitrust Trial; FTC Claims That Company Has Monopolized Social Media Market; Meta Says Agency Previously Blessed Instagram, WhatsApp Deals' - Bloomberg News

Susquehanna analyst Biju Perincheril maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Positive and lowers the price target from $10 to $8.

FLNC

Susquehanna Maintains Positive on Fluence Energy, Lowers Price Target to $8

Susquehanna analyst Biju Perincheril maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Neutral and lowers the price target from $76 to $59.

ENPH

Susquehanna Maintains Neutral on Enphase Energy, Lowers Price Target to $59

Scotiabank analyst Ovais Habib maintains K92 Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KNT#TSX">KNT</a>) with a Sector Outperform and raises the price target from C$11 to C$14.25.

Comments

Amprius Technologies

Noticias

Últimas noticias sobre Amprius Technologies (NYSE:AMPX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL